Literature DB >> 33490091

Identification of IL10RA by Weighted Correlation Network Analysis and in vitro Validation of Its Association With Prognosis of Metastatic Melanoma.

Si Cheng1,2, Zhe Li3, Wenhao Zhang4, Zhiqiang Sun1, Zhigang Fan5, Judong Luo1, Hui Liu4.   

Abstract

Skin cutaneous melanoma (SKCM) is the major cause of death for skin cancer patients, its high metastasis often leads to poor prognosis of patients with malignant melanoma. However, the molecular mechanisms underlying metastatic melanoma remain to be elucidated. In this study we aim to identify and validate prognostic biomarkers associated with metastatic melanoma. We first construct a co-expression network using large-scale public gene expression profiles from GEO, from which candidate genes are screened out using weighted gene co-expression network analysis (WGCNA). A total of eight modules are established via the average linkage hierarchical clustering, and 111 hub genes are identified from the clinically significant modules. Next, two other datasets from GEO and TCGA are used for further screening of biomarker genes related to prognosis of metastatic melanoma, and identified 11 key genes via survival analysis. We find that IL10RA has the highest correlation with clinically important modules among all identified biomarker genes. Further in vitro biochemical experiments, including CCK8 assays, wound-healing assays and transwell assays, have verified that IL10RA can significantly inhibit the proliferation, migration and invasion of melanoma cells. Furthermore, gene set enrichment analysis shows that PI3K-AKT signaling pathway is significantly enriched in metastatic melanoma with highly expressed IL10RA, indicating that IL10RA mediates in metastatic melanoma via PI3K-AKT pathway.
Copyright © 2021 Cheng, Li, Zhang, Sun, Fan, Luo and Liu.

Entities:  

Keywords:  IL10RA; WGCNA; metastatic melanoma; prognostic biomarker; skin cutaneous melanoma (SKCM); survival analysis

Year:  2021        PMID: 33490091      PMCID: PMC7820192          DOI: 10.3389/fcell.2020.630790

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  53 in total

1.  A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

Authors:  Robert W Ross; Matthew D Galsky; Howard I Scher; Jay Magidson; Karl Wassmann; Gwo-Shu Mary Lee; Leah Katz; Sumit K Subudhi; Aseem Anand; Martin Fleisher; Philip W Kantoff; William K Oh
Journal:  Lancet Oncol       Date:  2012-10-09       Impact factor: 41.316

2.  IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 3'-kinase.

Authors:  J H Zhou; S R Broussard; K Strle; G G Freund; R W Johnson; R Dantzer; K W Kelley
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

3.  IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway.

Authors:  Li Gao; Haige Han; Honglei Wang; Li Cao; Wen-Hai Feng
Journal:  Cancer Lett       Date:  2019-07-25       Impact factor: 8.679

4.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

5.  Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity.

Authors:  Sandip Bhattacharyya; Pradip Sen; Mark Wallet; Brian Long; Albert S Baldwin; Roland Tisch
Journal:  Blood       Date:  2004-04-27       Impact factor: 22.113

6.  Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.

Authors:  Liang Chen; Lushun Yuan; Yongzhi Wang; Gang Wang; Yuan Zhu; Rui Cao; Guofeng Qian; Conghua Xie; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

Review 7.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

8.  IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma.

Authors:  Isabella Venza; Maria Visalli; Concetta Beninati; Salvatore Benfatto; Diana Teti; Mario Venza
Journal:  BMC Med Genomics       Date:  2015-12-03       Impact factor: 3.063

9.  Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis.

Authors:  Jianing Tang; Deguang Kong; Qiuxia Cui; Kun Wang; Dan Zhang; Yan Gong; Gaosong Wu
Journal:  Front Oncol       Date:  2018-09-11       Impact factor: 6.244

10.  HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E.

Authors:  Xiaoyu Chang; Tianshun Zhang; Qiushi Wang; Moeez Ghani Rathore; Kanamata Reddy; Hanyong Chen; Seung Ho Shin; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Theranostics       Date:  2020-08-01       Impact factor: 11.556

View more
  4 in total

1.  Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma.

Authors:  Hejuan Hu; Bai Ling; Yuhan Shi; Haohao Wu; Bingying Zhu; Yiling Meng; Guo-Ming Zhang
Journal:  Front Oncol       Date:  2021-08-05       Impact factor: 6.244

2.  Down-regulated C4orf19 confers poor prognosis in colon adenocarcinoma identified by gene co-expression network.

Authors:  Wanpeng Wang; Xiaolu Lin; Ran Yu; Suqin Zhou; Yanyan Liu; Haifeng Jia; Feng Han; Yanzhi Bu; Juan Pu
Journal:  J Cancer       Date:  2022-01-09       Impact factor: 4.207

3.  Integrated weighted gene co-expression network analysis uncovers STAT1(signal transducer and activator of transcription 1) and IFI44L (interferon-induced protein 44-like) as key genes in pulmonary arterial hypertension.

Authors:  Han Yang; Yang Lu; Hongmin Yang; Yaoxi Zhu; Yaohan Tang; Lixia Li; Changhu Liu; Jing Yuan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Identification of Up-Regulated ANXA3 Resulting in Fracture Non-Union in Patients With T2DM.

Authors:  Changjiang Liu; Yuhang Liu; Yifeng Yu; Yong Zhao; Dong Zhang; Aixi Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.